Cytosorbents (CTSO) Set to Announce Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) is set to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. The company had revenue of $8.67 million for the quarter, compared to the consensus estimate of $9.29 million. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Price Performance

NASDAQ:CTSO opened at $0.93 on Wednesday. The company has a market cap of $50.63 million, a PE ratio of -1.46 and a beta of 0.62. Cytosorbents has a twelve month low of $0.78 and a twelve month high of $4.29. The company has a current ratio of 1.77, a quick ratio of 1.51 and a debt-to-equity ratio of 0.11. The company’s 50 day moving average is $0.91 and its two-hundred day moving average is $1.12.

Analyst Upgrades and Downgrades

CTSO has been the topic of several research analyst reports. StockNews.com initiated coverage on shares of Cytosorbents in a research report on Thursday, May 2nd. They set a “hold” rating on the stock. HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Tuesday.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.